With an aging global population, time is of the essence to find novel targets and therapies for age-related diseases.
A research team from Osaka University in Japan has concluded that a clinical trial of transplanted IPS cell-derived corneal tissue was safe and effective – further evidence that cellular reprogramming with Yamanaka factors is moving towards scalable therapies.
Longevity. Technology: The clinical trial spanned several years and used corneal tissues derived from induced pluripotent stem cells. The tissue was transplanted into four almost-blind patients, and, according to the research team, none of the patients experienced rejection or tumorigenicity of the transplanted cells and all saw improvements in their symptoms, with three experiencing improved eyesight, with one improving from 0.15 to 0.7. Importantly, all were free of side effects one year later.
IPS cells can be generated from any adult cell, with Yamanaka factors – a group of protein transcription factors from four master genes. These induced stem cells demonstrate the significant quality of pluripotency – they can differentiate into all other cell types of the body. This is incredibly useful both for research and for therapy.
Sun, Sep 11 at 12 PM CDT.
This is an invitation to the Annual General Meeting of the Cryonics Institute & the Immortalist Society.
The Cryonics Institute’s Annual General Meeting (AGM) will be held on Sunday, September 11th 2022 from 3:00pm to 6:30pm at the Infinity Hall & Sidebar 16,650 E. 14 Mile Rd, Fraser, MI 48,026 (USA). For more information visit www.infinityhallsidebar.com
Continue reading “Cryonics Institute’s Annual General Meeting 2022” »
This is not the first successful research on de-ageing cells. Earlier, Shinya Yamanaka, a Nobel prize-winning stem cell researcher, genetically reprogrammed the mouse skin cells and turned them into induced pluripotent stem cells, or iPSCs, back in 2006. These cells type had the potential to form any cell type in the body. Yamanaka’s method took 50 days and completely reprograms cells to the biological age of an embryo. Gill’s method only took 13 days.
In a statement, Gill said, “Our results represent a big step forward in our understanding of cell reprogramming. We have proved that cells can be rejuvenated without losing their function and that rejuvenation looks to restore some function to old cells.”
This is a 10-minute version with my picks on an hour-and-a-half interview on the longevity science made by Rhonda Patrick to Morgan Levine.
The link to the entire interview, which took place on April 12, 2022, is in the description of the video.
Continue reading “Morgan Levine is interviewed by Rhonda Patrick on Longevity. My picks on it” »
Making positive impacts on human longevity — sonia arrison, author, analyst, investor, entrepreneur.
Sonia Arrison (https://soniaarrison.com/) is a best-selling author, analyst, entrepreneur, and investor.
She gives a great analogy of slowing aging versus reversing aging, and I did not realize Yamanaka Factors were not so perfect in current use.
In this video Eleanor talks about the her view on Longevity Escape Velocity and reprogramming with Yamanaka factors and some of the issues around this technology.
Continue reading “Future Of Aging & Cellular Reprogramming | Eleanor Sheekey Ep 4” »
Organs age differently. To investigate the basis of organ-specific ageing we systematically compared at the tissue, stem cell and organoid level two organs representing ageing extremes, from accelera…
Trial will collect muscle aging biomarker data to inform Phase 2 trials and future development for muscle atrophy in hospitalised patients.
CARMAT, the developer of the world’s most advanced completely artificial heart has successfully raised €40.5 million in funding. The raise is set to finance the production of their Aeson artificial heart, which the company hopes will provide an alternative treatment option for people with heart failure – a condition affecting around 6.2 million adults in the US alone [1].
Longevity. Technology: Beating around 100,000 times per day, your heart works around the clock to keep your circulatory system ticking. The steady sound of your heartbeat is a comforting constant throughout your life. Forming the centre of the circulatory system, the heart continuously pumps blood around the body to deliver oxygen and nutrients to cells. Due to this constant work, our hearts can unfortunately wear out as we age, with cardiovascular diseases continuing to be the leading causes of death globally [2].
End-stage heart failure is a serious condition that occurs when the heart can no longer transport blood throughout the body effectively. It most often affects the left chamber of the heart, which pumps oxygen-rich blood around the body, leading to biventricular heart failure. Vital organs like the brain, liver and kidney fail to get enough oxygen and nutrients to function properly. With few treatment options, end-stage heart failure sometimes requires serious intervention like heart transplantation – considered the gold standard therapy. However, due to the global shortage in organ donors, this is not always possible and there is a gap for a therapeutic alternative that could have huge implications for longevity globally.
